COVID-19 vaccination a 12-month success for science, governments and industry

A little less conversation, a little more action please: the global state of AMR

Non-communicable diseases and the global countdown to 2030

The next 20-year PBS agenda: government commitments to new medicines spending

PBS New Medicines Funding Guarantee: echoes of elections past ...

The new frontier: emerging regulatory issues in cell and gene therapies

This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing

What future from a ‘no-deal’ Brexit for UK life sciences?

What would Dr Who say?: Time travel and the macroeconomic impact of COVID-19

President Trump’s new ‘Buy American’ executive order on essential medical products and implications

The economist, the activist and the epiphany: an argument about efficiency in health spending

Global trends in cardiovascular deaths: 30 years of country data

Spanish Flu vs COVID-19: medical technology and health system resilience

Covid-19 - So how are we doing? Lessons from USA, UK and France and how to move forward

Creeping Through the Backdoor: Disruption in Medicine and Health

When profit isn’t everything: 46,000 years of cultural history vs the iron ore spot price

Drones are taking off in healthcare

Space X and NASA: lessons on public-private R&D for the health debate

As diagnostic technology evolves – we will still need answers

Covid-19 - A vaccine will be a game changing addition but not a magic bullet